Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,464.03 -5.27 (-0.10%) Dow
38,963.66 -148.50 (-0.38%) Nasdaq
17,751.29 +33.64 (+0.19%) Bitcoin USD
61,742.18 +589.62 (+0.96%) CMC Crypto 200
1,277.67 -6.11 (-0.48%)
ITCI Jun 2024 85.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:29PM EDT. Market open.
| Previous close | 9.50 |
| Open | 10.00 |
| Bid | 18.40 |
| Ask | 21.20 |
| Strike | 85.00 |
| Expiry date | 2024-06-21 |
| Day's range | 7.70 - 10.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.